Please assess the completion status of the following clinical trial:

Trial Title: Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled Cardiac surgery for more than 24 hours~* High risk of perioperative transfusion defined by a TRUST Score ≥ 3~* Veno-Venous catheter in Superior vena cava territory~* Patient Affiliate or beneficiary of social security~* Collection on free, informed and written consent~Exclusion Criteria:~* EPO and FCM contraindication~* Patients already treated by EPO at the time of inclusion~* Non controlled Infectious endocarditis defined by ESC guidelines 2015~* Patients including in an other research~* Patients whose physical and/or psychological health is severely impaired and who, according to the investigator, may affect the participant's compliance with the study.~* Patients deprived from his rights (guardianship or tutelage measure)~* Patients who refuses to sign the consent~* pregnant or lactating woman

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- STOP Group (Type: EXPERIMENTAL): EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~* Hb \< 13g/dL the day before surgery~* Hb ≥ 7g/dL AND ScvO2 \> 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb \< 7g/dL independently of ScVO2 value
- Control Group (Type: NO_INTERVENTION): Only postoperative anemia will be managed:~* RBC transfusion will be performed if Hb ≤ 8 g/dL (2017 EACTS/EACTA guidelines)~* Iron sucrose administration if Hb \> 8g/dL : 2 injections of 200 mg according to Height (+/- 70 Kg) in 250 mL of saline solution 0.9% over 1h30 into 48 h intervals without exceeding a total dose of 15mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).